We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Onto Eastman Chemical (EMN) for Now
Read MoreHide Full Article
Eastman Chemical Company (EMN - Free Report) is gaining from cost-cutting and productivity actions as well as its innovation-driven growth model amid certain headwinds including higher raw material, energy and logistics costs.
Shares of this leading chemical maker are down 13.5% over the past year compared with the 4.8% decline of its industry.
Image Source: Zacks Investment Research
Let’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
What’s Aiding EMN?
Eastman Chemical is gaining from its actions to manage costs. The company is expected to benefit from lower operating costs from its operational transformation program and lower manufacturing shutdowns this year. It expects lower manufacturing and maintenance costs in 2022. The company’s cost actions are expected to contribute to its earnings per share this year.
The company is also focused on generating new business revenues from innovation. Eastman Chemical generated roughly $600 million of new business revenues from innovation in 2021, driven by the strength in its specialty products. The company expects its specialty portfolio to drive sales growth across major markets such as consumer durables, building & construction, and transportation in 2022.
Eastman Chemical will also gain from its strategic acquisitions and pricing actions to counter the cost inflation. Strong end-market demand is also supporting its top line growth. The company is seeing strong demand in major markets, including building and construction, personal care, and animal nutrition.
Eastman Chemical is also committed toward maintaining a disciplined approach to capital allocation, with an emphasis on financing its dividend and debt reduction. The company returned $1.4 billion to shareholders through share repurchases and dividends during 2021. Eastman Chemical also repaid $350 million of debt in 2021. The company also returned $98 million to its shareholders through dividends in the last reported quarter. It expects to buyback more than $1 billion of shares in 2022. Eastman Chemical also expects to generate operating cash flow of around $1.6 billion in 2022.
A Few Headwinds
Eastman Chemical faces headwinds from higher raw material, energy and distribution costs in some of its products. It saw significant headwinds from higher raw material, energy and distribution costs in the first quarter of 2022. These costs are expected to remain at the high levels in 2022.
The company is also exposed to headwinds from supply-chain disruptions, partly associated with the pandemic. It witnessed unfavorable impacts from supply chain constraints and higher logistics costs in the first quarter. Headwinds associated with supply and logistics are likely to continue to impact its second-quarter 2022 results.
The company also faces challenges from the slowdown in automotive production. The semiconductor shortage is affecting automotive production globally. The Russia-Ukraine conflict has exacerbated the chip crisis. Weaker automotive production due to component shortages is likely to affect demand in this market over the near term.
Better-ranked stocks worth considering in the basic materials space include Nutrien Ltd. (NTR - Free Report) , Allegheny Technologies Inc. (ATI - Free Report) and Cabot Corporation (CBT - Free Report) .
Nutrien, sporting a Zacks Rank #1 (Strong Buy), has an expected earnings growth rate of 169.6% for the current year. The Zacks Consensus Estimate for NTR's current-year earnings has been revised 27.5% upward over the last 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nutrien beat the Zacks Consensus Estimate for earnings in three of the last four quarters while missed once. It has a trailing four-quarter earnings surprise of roughly 5.8%, on average. NTR has rallied roughly 36% in a year.
Allegheny has a projected earnings growth rate of 953.9% for the current year. The Zacks Consensus Estimate for ATI's current-year earnings has been revised 31.7% upward in the past 60 days.
Allegheny’s earnings beat the Zacks Consensus Estimate in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 128.9%, on average. ATI has gained around 8% in a year and currently sports a Zacks Rank #1.
Cabot, currently carrying a Zacks Rank #1, has an expected earnings growth rate of 21.5% for the current fiscal year. The Zacks Consensus Estimate for CBT's earnings for the current fiscal has been revised 5.2% upward in the past 60 days.
Cabot’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 16.2%. CBT has gained around 19% over a year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold Onto Eastman Chemical (EMN) for Now
Eastman Chemical Company (EMN - Free Report) is gaining from cost-cutting and productivity actions as well as its innovation-driven growth model amid certain headwinds including higher raw material, energy and logistics costs.
Shares of this leading chemical maker are down 13.5% over the past year compared with the 4.8% decline of its industry.
Image Source: Zacks Investment Research
Let’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
What’s Aiding EMN?
Eastman Chemical is gaining from its actions to manage costs. The company is expected to benefit from lower operating costs from its operational transformation program and lower manufacturing shutdowns this year. It expects lower manufacturing and maintenance costs in 2022. The company’s cost actions are expected to contribute to its earnings per share this year.
The company is also focused on generating new business revenues from innovation. Eastman Chemical generated roughly $600 million of new business revenues from innovation in 2021, driven by the strength in its specialty products. The company expects its specialty portfolio to drive sales growth across major markets such as consumer durables, building & construction, and transportation in 2022.
Eastman Chemical will also gain from its strategic acquisitions and pricing actions to counter the cost inflation. Strong end-market demand is also supporting its top line growth. The company is seeing strong demand in major markets, including building and construction, personal care, and animal nutrition.
Eastman Chemical is also committed toward maintaining a disciplined approach to capital allocation, with an emphasis on financing its dividend and debt reduction. The company returned $1.4 billion to shareholders through share repurchases and dividends during 2021. Eastman Chemical also repaid $350 million of debt in 2021. The company also returned $98 million to its shareholders through dividends in the last reported quarter. It expects to buyback more than $1 billion of shares in 2022. Eastman Chemical also expects to generate operating cash flow of around $1.6 billion in 2022.
A Few Headwinds
Eastman Chemical faces headwinds from higher raw material, energy and distribution costs in some of its products. It saw significant headwinds from higher raw material, energy and distribution costs in the first quarter of 2022. These costs are expected to remain at the high levels in 2022.
The company is also exposed to headwinds from supply-chain disruptions, partly associated with the pandemic. It witnessed unfavorable impacts from supply chain constraints and higher logistics costs in the first quarter. Headwinds associated with supply and logistics are likely to continue to impact its second-quarter 2022 results.
The company also faces challenges from the slowdown in automotive production. The semiconductor shortage is affecting automotive production globally. The Russia-Ukraine conflict has exacerbated the chip crisis. Weaker automotive production due to component shortages is likely to affect demand in this market over the near term.
Eastman Chemical Company Price and Consensus
Eastman Chemical Company price-consensus-chart | Eastman Chemical Company Quote
Stocks to Consider
Better-ranked stocks worth considering in the basic materials space include Nutrien Ltd. (NTR - Free Report) , Allegheny Technologies Inc. (ATI - Free Report) and Cabot Corporation (CBT - Free Report) .
Nutrien, sporting a Zacks Rank #1 (Strong Buy), has an expected earnings growth rate of 169.6% for the current year. The Zacks Consensus Estimate for NTR's current-year earnings has been revised 27.5% upward over the last 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nutrien beat the Zacks Consensus Estimate for earnings in three of the last four quarters while missed once. It has a trailing four-quarter earnings surprise of roughly 5.8%, on average. NTR has rallied roughly 36% in a year.
Allegheny has a projected earnings growth rate of 953.9% for the current year. The Zacks Consensus Estimate for ATI's current-year earnings has been revised 31.7% upward in the past 60 days.
Allegheny’s earnings beat the Zacks Consensus Estimate in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 128.9%, on average. ATI has gained around 8% in a year and currently sports a Zacks Rank #1.
Cabot, currently carrying a Zacks Rank #1, has an expected earnings growth rate of 21.5% for the current fiscal year. The Zacks Consensus Estimate for CBT's earnings for the current fiscal has been revised 5.2% upward in the past 60 days.
Cabot’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 16.2%. CBT has gained around 19% over a year.